Literature DB >> 24255916

Diverse T-cell responses characterize the different manifestations of cutaneous graft-versus-host disease.

Marie-Charlotte Brüggen1, Irene Klein, Hildegard Greinix, Wolfgang Bauer, Zoya Kuzmina, Werner Rabitsch, Peter Kalhs, Peter Petzelbauer, Robert Knobler, Georg Stingl, Georg Stary.   

Abstract

Graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (HCT) and can present in an acute (aGVHD), a chronic lichenoid (clGVHD), and a chronic sclerotic form (csGVHD). It is unclear whether similar or different pathomechanisms lead to these distinct clinical presentations. To address this issue, we collected lesional skin biopsies from aGVHD (n = 25), clGVHD (n = 17), and csGVHD (n = 7) patients as well as serial nonlesional biopsies from HCT recipients (prior to or post-HCT) (n = 14) and subjected them to phenotypic and functional analyses. Our results revealed striking differences between aGVHD and clGVHD. In aGVHD, we found a clear predominance of T helper (Th)2 cytokines/chemokines and, surprisingly, of interleukin (IL)-22 messenger RNA as well as an increase of IL-22-producing CD4(+) T cells. Thymic stromal lymphopoietin, a cytokine skewing the immune response toward a Th2 direction, was elevated at day 20 to 30 post-HCT in the skin of patients who later developed aGVHD. In sharp contrast to aGVHD, the immune response occurring in clGVHD showed a mixed Th1/Th17 signature with upregulated Th1/Th17 cytokine/chemokine transcripts and elevated numbers of interferon-γ- and IL-17-producing CD8(+) T cells. Our findings shed new light on the T-cell responses involved in the different manifestations of cutaneous GVHD and identify molecular signatures indicating the development of the disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24255916     DOI: 10.1182/blood-2013-07-514372

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  39 in total

1.  An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition.

Authors:  Edouard Forcade; Katelyn Paz; Ryan Flynn; Brad Griesenauer; Tohti Amet; Wei Li; Liangyi Liu; Giorgos Bakoyannis; Di Jiang; Hong Wei Chu; Mercedes Lobera; Jianfei Yang; David S Wilkes; Jing Du; Kate Gartlan; Geoffrey R Hill; Kelli Pa MacDonald; Eduardo L Espada; Patrick Blanco; Jonathan S Serody; John Koreth; Corey S Cutler; Joseph H Antin; Robert J Soiffer; Jerome Ritz; Sophie Paczesny; Bruce R Blazar
Journal:  JCI Insight       Date:  2017-06-15

2.  Inhibition of EGFR Tyrosine Kinase by Erlotinib Prevents Sclerodermatous Graft-Versus-Host Disease in a Mouse Model.

Authors:  Florence Morin; Niloufar Kavian; Wioleta Marut; Christiane Chéreau; Olivier Cerles; Philippe Grange; Bernard Weill; Carole Nicco; Frédéric Batteux
Journal:  J Invest Dermatol       Date:  2015-05-04       Impact factor: 8.551

Review 3.  Cytokine mediators of chronic graft-versus-host disease.

Authors:  Kelli Pa MacDonald; Bruce R Blazar; Geoffrey R Hill
Journal:  J Clin Invest       Date:  2017-06-30       Impact factor: 14.808

Review 4.  Acute graft-versus-host disease: a bench-to-bedside update.

Authors:  Shernan G Holtan; Marcelo Pasquini; Daniel J Weisdorf
Journal:  Blood       Date:  2014-06-09       Impact factor: 22.113

5.  Epidermal elafin expression is an indicator of poor prognosis in cutaneous graft-versus-host disease.

Authors:  Marie-Charlotte Brüggen; Peter Petzelbauer; Hildegard Greinix; Emmanuel Contassot; Dragana Jankovic; Lars French; Gérard Socié; Werner Rabitsch; Zoya Kuzmina; Peter Kalhs; Robert Knobler; Georg Stingl; Georg Stary
Journal:  J Invest Dermatol       Date:  2014-11-18       Impact factor: 8.551

Review 6.  Interleukin-22: immunobiology and pathology.

Authors:  Jarrod A Dudakov; Alan M Hanash; Marcel R M van den Brink
Journal:  Annu Rev Immunol       Date:  2015-02-11       Impact factor: 28.527

7.  Upregulation of IFN-Inducible and Damage-Response Pathways in Chronic Graft-versus-Host Disease.

Authors:  Frances T Hakim; Sarfraz Memon; Ping Jin; Matin M Imanguli; Huan Wang; Najibah Rehman; Xiao-Yi Yan; Jeremy Rose; Jacqueline W Mays; Susan Dhamala; Veena Kapoor; William Telford; John Dickinson; Sean Davis; David Halverson; Haley B Naik; Kristin Baird; Daniel Fowler; David Stroncek; Edward W Cowen; Steven Z Pavletic; Ronald E Gress
Journal:  J Immunol       Date:  2016-09-30       Impact factor: 5.422

Review 8.  Chronic graft-versus-host disease: biological insights from preclinical and clinical studies.

Authors:  Kelli P A MacDonald; Geoffrey R Hill; Bruce R Blazar
Journal:  Blood       Date:  2016-11-07       Impact factor: 22.113

9.  Approaches for the prevention of graft-versus-host disease following hematopoietic cell transplantation.

Authors:  Erin Gatza; Sung Won Choi
Journal:  Int J Hematol Oncol       Date:  2015-08

Review 10.  Physical function and quality of life in patients with chronic GvHD: a summary of preclinical and clinical studies and a call for exercise intervention trials in patients.

Authors:  C Fiuza-Luces; R J Simpson; M Ramírez; A Lucia; N A Berger
Journal:  Bone Marrow Transplant       Date:  2015-09-14       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.